Review Article
Update on Chemotherapy in the Treatment of Urothelial Carcinoma
Table 2
Ongoing clinical trials with targeted agents in urothelial carcinoma.
| Phase | Cohort | Subjects | Treatment | Protocol number |
| I/II | Noncystectomy candidates undergoing radiation in muscle-invasive disease | 88 | Paclitaxel ± trastuzumab | NCT00238420 |
| I | First line metastatic/advanced | 25 | GC with lapatinib | NCT00623064 |
| II/III | Maintenance after first-line metastatic/advanced | 204 | Lapatinib versus placebo | NCT00949455 |
| II | First-line metastatic/advanced | 86 | GC ± cetuximab | NCT00645593 |
| II | First-line metastatic/advanced | 51 | GC with bevacizumab | NCT00588666 |
| III | First-line metastatic/advanced | 500 | GC ± bevacizumab | NCT00942331 |
| II | Neoadjuvant/adjuvant | 25 | Neoadjuvant GC with bevacizumab Adjuvant paclitaxel with bevacizumab | NCT00268450 |
| II | Neoadjuvant | 45 | GC with sunitinib | NCT00847015 |
| II | Adjuvant | 33 | Sunitinib (after neoadjuvant platinum-based chemotherapy) | NCT01042795 |
| II | First-line cisplatin ineligible metastatic/advanced | 41 | Sunitinib | NCT01118039 |
| II | First-line metastatic/advanced | 63 | GC with sunitinib | NCT01089088 |
| II | Neoadjuvant | 45 | GC with sorafenib | NCT01222676 |
| II | First line metastatic/advanced | 30 | GC with sorafenib | NCT00461851 |
| I | Non-cystectomy candidates undergoing radiation in muscle invasive disease | 18 | Sorafenib | NCT00544609 |
| II | Second-line cisplatin pretreated metastatic/advanced | 41 | Pazopanib | NCT01031875 |
| II | Second- or third-line metastatic | 32 | Pazopanib with weekly paclitaxel | NCT01108055 |
| Pilot | Neoadjuvant | 25 | Dasatinib | NCT00706641 |
| II | First-line cisplatin ineligible metastatic/advanced | 122 | Carboplatin/Gemcitabine ± vandetanib | NCT01191892 |
|
|
*Data from http://www.clinicaltrials.gov/ accessed on April 2011.
|